146 related articles for article (PubMed ID: 21970190)
1. Budget impact analysis of pemetrexed introduction: case study from a teaching hospital perspective, Thailand.
Chanjaruporn F; Roughead EE; Sooksriwong CO; Kaojarern S
J Med Assoc Thai; 2011 Sep; 94(9):1026-34. PubMed ID: 21970190
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
[TBL] [Abstract][Full Text] [Related]
4. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Carlson JJ; Wong WB; Veenstra DL; Reyes C
J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
[TBL] [Abstract][Full Text] [Related]
6. The mounting medical care cost for adult AIDS patients at the Faculty of Medicine, Siriraj Hospital: consideration for management.
Suwanagool S; Ratanasuwan W; Techasathit W
J Med Assoc Thai; 1997 Jul; 80(7):431-9. PubMed ID: 9277072
[TBL] [Abstract][Full Text] [Related]
7. Costs of payment in Thai acute coronary syndrome patients.
Moleerergpoom W; Kanjanavanit R; Jintapakorn W; Sritara P
J Med Assoc Thai; 2007 Oct; 90 Suppl 1():21-31. PubMed ID: 18431883
[TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y; Bagust A; Dickson R; Dodd S; Green J; Haycox A; Hill R; McLeod C; Walley T
Health Technol Assess; 2007 Jan; 11(1):1-90. PubMed ID: 17181984
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
11. Pem and the cost of multicycle maintenance.
Learn PA; Bach PB
J Thorac Oncol; 2010 Aug; 5(8):1111-2. PubMed ID: 20661082
[No Abstract] [Full Text] [Related]
12. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
[TBL] [Abstract][Full Text] [Related]
14. A cost function analysis of shigellosis in Thailand.
Riewpaiboon A; Youngkong S; Sreshthaputra N; Stewart JF; Samosornsuk S; Chaicumpa W; von Seidlein L; Clemens JD
Value Health; 2008 Mar; 11 Suppl 1():S75-83. PubMed ID: 18387071
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective.
Purmonen TT; Auvinen PK; Martikainen JA
Int J Technol Assess Health Care; 2010 Apr; 26(2):163-9. PubMed ID: 20392319
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
17. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC).
Mueller E
Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456
[No Abstract] [Full Text] [Related]
19. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
20. Unit cost analysis in a university hospital: an example from Srinagarind Hospital, Khon Kaen.
Vatanasapt V; Kosuwon W; Pengsaa P
J Med Assoc Thai; 1993 Dec; 76(12):647-53. PubMed ID: 7798815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
